Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
China Pegaspargase Markets, 2013-2017, 2018 & 2019-2023 | ||
By: PR Newswire Association LLC. - 16 Sep 2019 | Back to overview list |
|
DUBLIN, Sept. 16, 2019 /PRNewswire/ -- The "Investigation Report on China's Pegaspargase Market, 2019-2023" report has been added to ResearchAndMarkets.com's offering. The sales value of Pegaspargase kept rising after the drug was launched in China. In 2017, it reached about CNY 74 million, representing a CAGR of 20.10% from 2013 to 2017. As environmental pollution and decoration pollution worsens, the number of leukemia patients in China will keep increasing. Therefore, the market size of Pegaspargase in China will continue to expand from 2019 to 2023. By then, in addition to Aiyang by Jiangsu Hengrui Medicine Co., Ltd., more Pegaspargase products will be approved to be put on the market. According to the report, branded Pegaspargase (trade name: Oncaspar) was developed by Enzon Pharmaceuticals, Inc. In 1994, it was approved by the FDA to be applied to those who have acute lymphoblastic leukemia and are allergic to L-asparaginase. In 2000, it was approved by the FDA to be used in the first-line treatment of newly diagnosed leukemia patients. For many reasons, Oncaspar has not been approved to be sold in China. In 2009, the generic Pegaspargase injection developed by Jiangsu Hengrui Medicine Co., Ltd. was approved by the CFDA to be sold in China. By Aug. 2019, only Jiangsu Hengrui Medicine Co., Ltd. has been approved to sell Pegaspargase in China. Other Chinese pharmaceutical companies such as Beijing SL Pharmaceutical Co., Ltd. are also developing generic Pegaspargase. Their Pegaspargase products are expected to be launched in China by 2023.
Key Topics Covered: 1 Relevant Concepts of Pegaspargase For more information about this report visit https://www.researchandmarkets.com/r/2ltoa4 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets View original content:http://www.prnewswire.com/news-releases/china-pegaspargase-markets-2013-2017-2018--2019-2023-300918930.html SOURCE Research and Markets |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |